We thank Tong and colleagues1 for their report on a patient with schizophrenia and clozapine-induced maculopathy, and for highlighting this under-recognised condition.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Tong JY, Pai A, Heydon P, Young SH. Clozapine-induced maculopathy. Med J Aust 2017; 206: 246. <MJA full text>
- 2. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs 2010; 24: 501-526.
- 3. Faure C, Audo I, Zeitz C, Letessier JB, Robert MP. Aripiprazole-induced chorioretinopathy: multimodal imaging and electrophysiological features. Doc Ophthalmol 2015; 131: 35-41.
- 4. Lee MS, Fern AI. Fluphenazine and its toxic maculopathy. Ophthalmic Res 2004; 36: 237-239.
- 5. Borovik AM, Bosch MM, Watson SL. Ocular pigmentation associated with clozapine. Med J Aust 2009; 190: 210-211. <MJA full text>
- 6. Clemens CR, Alten F, Loos D, et al. Poppers maculopathy or retinopathy? Eye 2015; 29: 148-149.
- 7. Ascaso FJ, Rodriguez-Jimenez R, Cabezón L, et al. Retinal nerve fiber layer and macular thickness in patients with schizophrenia: Influence of recent illness episodes. Psychiatry Res 2015; 229: 230-236.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.